Cann Group Ltd
ASX:CAN
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Cann Group Ltd
ASX:CAN
|
9.5m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
976.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
294.6B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Cann Group Ltd
Glance View
Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation facility near Mildura, Victoria. The company focuses on developing and supplying cannabis, cannabis resin and medicinal cannabis products into the Australian market. The firm has a cannabis research license and cannabis cultivation license. The cannabis cultivation license allows the Company to produce Australian grown material that can be prescribed for patient use. The company focuses on plant genetics, breeding, cultivation, extraction, analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Cann Group Ltd is 68.2%, which is above its 3-year median of 37.9%.
Over the last 2 years, Cann Group Ltd’s Gross Margin has increased from 21.2% to 68.2%. During this period, it reached a low of 21.2% on Dec 31, 2023 and a high of 68.2% on Jul 30, 2025.
